The firm is a U.S.-based venture capital investor focused on Seed through growth-stage deep-tech companies, including opportunities across healthcare. The firm invests through direct and special-purpose investment structures and can access matching capital of up to $10M for qualifying companies willing to establish operations in a designated U.S. innovation ecosystem. The firm primarily targets companies with differentiated technologies and evidence of meaningful technical or commercial validation.
Within healthcare, the firm focuses primarily on healthtech, including digital health and medical technology. For therapeutics, the firm selectively considers companies addressing compelling disease areas through novel technologies and generally requires programs to have completed Phase I development or otherwise achieved substantial technical and clinical de-risking. For digital health opportunities, the firm requires demonstrated customer traction and a minimum level of commercial revenue. Pre-revenue pharmaceutical companies may be considered when meaningful alternative indicators of traction and validation can be demonstrated.
From a company and management team perspective, the firm seeks companies that can demonstrate clear evidence of technology validation, market traction, or clinical de-risking appropriate to their sector and development stage. The firm takes an active governance approach and requires a board seat as part of its investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
